Childhood optic tract astrocytoma

Summary

Childhood optic tract astrocytoma (MONDO:0003931) is a disease. A subtype of childhood cerebral astrocytoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	childhood optic tract astrocytoma
Mondo ID	MONDO:0003931
DOID	DOID:6575
NCIT	C7534
UMLS	C1333014
MedGen	232072
GARD	0023743
Is cancer (heuristic)	no

Also known as: childhood visual pathway astrocytoma · optic tract astrocytoma of childhood · paediatric optic tract astrocytoma · paediatric visual pathway astrocytoma · pediatric optic tract astrocytoma · pediatric visual pathway astrocytoma

Disease family

This is a subtype of childhood cerebral astrocytoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › childhood neoplasm › childhood astrocytic tumor › childhood cerebral astrocytoma › childhood optic tract astrocytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.